Table 4.

Acute toxicities in high-risk oral cavity cancer patients treated with postoperative helical tomotherapy (HT, image-guided radiotherapy, IGRT) and intensity-modulated radiotherapy (IMRT, non- image-guided radiotherapy, non-IGRT) with or without concurrent chemoradiation therapy (CCRT)

bToxicity	IMRT (non-IGRT) (No. = 79)	HT (IGRT) (No. = 73)	P value
		No. of patients (%)
aXerostomia (Acute)
Gr.1	54 (68.4 %)	54 (74.0 %)	0.445
Gr.2	25 (31.6 %)	19 (26.0 %)
Gr.3	0	0
Gr.4	0	0
Gr.5	0	0
Mucositis
Gr.1	7 (8.9 %)	4 (5.5 %)	0.627
Gr.2	49 (62.0 %)	44 (60.3 %)
Gr.3	23 (29.1 %)	25 (34.2 %)
Gr.4	0	0
Gr.5	0	0
Dermatitis
Gr.1	33 (41.8 %)	33 (45.2 %)	0.180
Gr.2	30 (47.6 %)	33 (45.2 %)
Gr.3	16 (20.3 %)	7 (9.6 %)
Gr.4	0	0
Gr.5	0	0
Body weight loss
Gr.1	51 (64.6 %)	62 (84.9 %)	0.004
Gr.2	27 (34.2 %)	11 (15.1 %)
Gr.3	1 (1.3 %)	0
Gr.4	0	0
Gr.5	0	0
Dysphagia
Gr.1	53 (67.1 %)	55 (75.3 %)	0.472
Gr.2	11 (13.9 %)	9 (12.3 %)
Gr.3	15 (19.0 %)	9 (12.3 %)
Gr.4	0	0
Gr.5	0	0
Fistula formation or superficial cases of skin dehiscence
Yes	1 (1.3 %)	3 (4.1 %)	0.351
No	78 (98.7 %)	70 (95.9 %)
Anemia
Normal	11 (13.9 %)	15 (20.5 %)	0.507
Gr.1	58 (73.4 %)	51 (69.9 %)
Gr.2	10(12.7 %)	7 (9.6 %)
Gr.3	0	0
Gr.4	0	0
Gr.5	0	0
Leucopenia
Normal	14 (17.7 %)	24 (32.9 %)	0.007
Gr.1	49 (62.0 %)	25 (34.2 %)
Gr.2	9 (11.4 %)	17 (23.3 %)
Gr.3	5 (6.3 %)	6 (8.2 %)
Gr.4	2 (2.5 %)	1 (1.4 %)
Gr.5	0	0
Thrombocytopenia
Normal	15 (19.0 %)	31 (42.5 %)	0.003
Gr.1	59 (74.7 %)	41 (56.2 %)
Gr.2	3 (3.8 %)	1 (1.4 %)
Gr.3	2 (2.5 %)	0
Gr.4	0	0
Gr.5	0	0

^aAcute xelostomia: Acute toxicity is defined as occurring < 90 days after beginning RT

^bToxicity grade was determined according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0)